ZTS
Zoetis Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum-inputs (vergelijkbare managers):
breedte van houders -3.8% ·
aandelenstroom +0.2% ·
netto nieuwe posities -8.0%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 944.24K | $65.94M | n/a | n/a |
| Q2 2026 | 175 | +5 | 282.45M | $20.33B | +9 | −3 |
| Q1 2026 | 172 | -5 | 287.89M | $34.03B | +1 | −7 |
| Q4 2025 | 176 | -2 | 318.69M | $40.10B | +3 | −4 |
| Q3 2025 | 25 | -1 | 154.48M | $22.59B | n/a | −2 |
| Q2 2025 | 24 | +2 | 132.57M | $20.67B | +2 | n/a |
| Q1 2025 | 19 | 0 | 50.59M | $8.32B | n/a | n/a |
| Q4 2024 | 19 | +1 | 54.43M | $8.86B | +1 | n/a |
| Q3 2024 | 17 | 0 | 31.69M | $6.18B | +1 | −1 |
| Q2 2024 | 17 | n/a | 38.28M | $6.63B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 42.31M | +1.0% | $6.19B | 0.1% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passief) | 36.20M | -2.8% | $5.30B | 0.1% | ▼ Trim | 2 | SEC ↗ ×21 |
| 3 | State Street Global Advisors ✦ (passief) | 19.65M | -0.5% | $2.87B | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 16.94M | n/a | $2.48B | 0.1% | n/c | 1 | SEC ↗ ×25 |
| 5 | Geode Capital Management ✦ (passief) | 11.14M | +0.5% | $1.62B | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Wellington Management ✦ | 8.54M | -3.9% | $1.25B | 0.2% | ▼ Trim | 6 | SEC ↗ ×5 |
| 7 | JPMorgan Chase ✦ | 5.22M | n/a | $763.17M | 0.0% | n/c | 1 | SEC ↗ ×38 |
| 8 | Goldman Sachs Group ✦ | 4.59M | n/a | $671.30M | 0.1% | n/c | 1 | SEC ↗ ×5 |
| 9 | Arrowstreet Capital ✦ | 2.70M | +83.4% | $394.75M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 1.60M | +108.1% | $233.75M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 1.54M | +25.6% | $221.94M | 0.1% | ▲ Add | 6 | SEC ↗ ×7 |
| 12 | T. Rowe Price ✦ | 1.04M | +6.6% | $152.06M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 13 | Fidelity (FMR) ✦ | 685.88K | -37.0% | $100.36M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 14 | Marshall Wace ✦ | 594.38K | +1276.4% | $86.97M | 0.1% | ▲ Add | 6 | SEC ↗ ×3 |
| 15 | Capital World Investors ✦ | 394.43K | -43.3% | $57.71M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 370.23K | -47.9% | $54.17M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 17 | Millennium Management ✦ | 329.60K | -71.9% | $48.23M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 256.90K | +171.6% | $37.59M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 125.59K | +96.2% | $18.38M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 113.59K | +722.3% | $16.62M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 74.80K | +33.0% | $10.94M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 22 | Adage Capital Partners ✦ | 60.10K | -58.6% | $8.79M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 23 | GAMCO Investors ✦ | 14.51K | -7.5% | $2.12M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 24 | Fisher Asset Management ✦ | 2.38K | -8.6% | $347,785 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 25 | Dodge & Cox ✦ | 1.50K | 0.0% | $219,480 | 0.0% | Held | 6 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Norges Bank | $809.49M | was 0.1% |
| Harris Associates (Oakmark) | $219,110 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1,596 houders, 404.54M aandelen, $46.32B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.